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The role of mitochondrial labile iron in
Friedreich’s ataxia skin fibroblasts sensitivity
to ultraviolet A†
Olivier Reelfs, ‡a Vincenzo Abbate,‡bc Agostino Cilibrizzi, b Mark A. Pook,d
Robert C. Hiderb and Charareh Pourzand*a
Mitochondrial labile iron (LI) is a major contributor to the susceptibility of skin fibroblasts to ultraviolet
A (UVA)-induced oxidative damage leading to necrotic cell death via ATP depletion. Mitochondria iron
overload is a key feature of the neurodegenerative disease Friedreich’s ataxia (FRDA). Here we show that
cultured primary skin fibroblasts from FRDA patients are 4 to 10-fold more sensitive to UVA-induced
death than their healthy counterparts. We demonstrate that FRDA cells display higher levels of
mitochondrial LI (up to 6-fold on average compared to healthy counterparts) and show higher increase
in mitochondrial reactive oxygen species (ROS) generation after UVA irradiation (up to 2-fold on
average), consistent with their differential sensitivity to UVA. Pre-treatment of the FRDA cells with a
bespoke mitochondrial iron chelator fully abrogates the UVA-mediated cell death and reduces UVA-
induced damage to mitochondrial membrane and the resulting ATP depletion by a factor of 2.
Our results reveal a link between FRDA as a disease of mitochondrial iron overload and sensitivity to
UVA of skin fibroblasts. Our findings suggest that the high levels of mitochondrial LI in FRDA cells which
contribute to high levels of mitochondrial ROS production after UVA irradiation are likely to play a
crucial role in the marked sensitivity of these cells to UVA-induced oxidative damage. This study may
have implications not only for FRDA but also for other diseases of mitochondrial iron overload, with the
view to develop topical mitochondria-targeted iron chelators as skin photoprotective agents.
Significance to metallomics
Iron is a vital element for cell processes such as mitochondrial energy production. In Friedreich’s ataxia (FRDA), dysregulation of iron metabolism causes
mitochondrial iron overload, leading to excess reactive oxygen species production and cytotoxicity. We report that high levels of mitochondrial iron in skin cells
from FRDA patients render them extremely sensitive to oxidative stress induced by solar ultraviolet A (UVA) compared to their healthy counterparts. Moreover,
a bespoke mitochondrial iron-trapping molecule protects the FRDA-affected skin cells from UVA-induced damage. This study highlights the sensitivity to UVA
as a novel connection to FRDA and possibly other mitochondrial iron overload disorders.
Introduction
Iron is an indispensable element for life as it participates in
several crucial cellular functions.1 However, iron can also be
potentially cytotoxic when present in the form of redox-active
chelatable labile iron (LI) which can act as catalyst in the
formation of harmful reactive oxygen species (ROS) such as
hydroxyl radical via Fenton chemistry.2 Hence, levels of LI
are normally tightly regulated in cells. The majority of the
intracellular LI resides in subcellular compartments, with
mitochondria, the main cellular site of iron metabolism having
been shown to be the major destination of LI.3–5 Due to their
function in respiration, mitochondria are also the primary
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source of ROS in cells, hence the presence of high chelatable LI
in mitochondria renders these organelles particularly susceptible
to oxidative stress conditions. We have previously demonstrated
that mitochondria are a major target of UVA radiation-induced
damage in skin fibroblasts leading to ATP depletion and the
ensuing necrotic cell death.6–9 Subsequently we showed that
targeting the mitochondrial LI of skin fibroblasts with a highly
specific chelator provides an unprecedented protection against
UVA-mediated oxidative damage to the organelle and the resulting
cell death.10
In view of the central role of mitochondria in cells, it is not
surprising that deregulation of mitochondrial iron metabolism,
such as that which occurs in Friedreich’s ataxia (FRDA), has
profound consequences on cell integrity and function. FRDA is
a disease caused by deficient levels of frataxin (FXN), a mito-
chondrial protein11 which plays a key role as an iron chaperone
in the synthesis of heme and iron sulfur clusters (ISCs) and also
in antioxidant protection.12,13 A major long-term consequence
of pathological or genetically-mediated reduction of FXN levels
in cells and tissues is mitochondrial iron overload which has
been linked to progressive mitochondria dysfunction, impairment
of energy metabolism and accumulation of intracellular oxidative
damage.14–17 Furthermore, cultured skin fibroblasts from FRDA
patients show defects in antioxidant mechanisms18–20 and are
more sensitive than their healthy counterparts to various forms of
chemically-induced oxidative stress,21 including exogenous iron
and H2O2.
22,23 Both iron- and H2O2-induced cytotoxicity can be
partially reversed when cells are pre-treated with iron chelators,
implying an important contribution from mitochondrial LI in
oxidative injury. Treatment of a mouse model of FRDA with highly
lipophilic iron chelators mitigated the symptoms of the disease
on the heart, further supporting the benefits of this approach.24
Furthermore, treatment of cells with deferiprone (DFP), a
membrane-permeable bidentate iron chelator reduced oxidative
damage to mitochondrial proteins.25,26 Several clinical trials have
demonstrated the therapeutic benefits of DFP – used alone or in
combination with other molecules, in the treatment of FRDA.26–28
Clearly the use of iron chelators to reinstate mitochondria func-
tions and cell/tissue integrity in FRDA has potential. Nevertheless,
all the chelators used so far systemically – including DFP, have
drawbacks related to their lack of target specificity for the site of
damage (i.e. mitochondria) and the consequent risks including
disruption of normal homeostasis and depletion of patient’s iron
levels, resulting in anaemia. Hence there is a clear need to design
iron chelators with improved properties, such as targeting them to
their site of action, the mitochondria.
One approach to reduce/avoid unwanted effects and improve
the effectiveness of the chelator consists in targeting the chelating
unit to the mitochondria by linking it to a mitochondria-specific
‘‘SS peptide’’. Such peptides, based on alternate hydrophobic
and basic amino acid side chains readily permeate cell plasma
membranes and selectively accumulate in the mitochondria.29–32
We have recently developed and characterized two distinct
classes of fluorescent bidentate iron chelators selectively
directed to mitochondria and acting as iron sensors.29,33–37
Furthermore, we demonstrated the successful use of a hexadentate
mitochondria-targeted iron chelator in photoprotection of cultured
skin fibroblasts against solar UVA (320–400 nm)-induced mito-
chondria damage and ensuing cell death.10
Because mitochondrial iron overload has been recognised as
a key feature of FRDA,38,39 we hypothesized that FRDA patients
might be more susceptible to UVA-induced skin damage than
healthy counterparts. Here we show that skin fibroblasts from
FRDA patients are highly sensitive to UVA-induced cytotoxicity
compared to their healthy counterparts. This correlated
with the higher basal level of mitochondrial LI in FRDA cells
which contributes to higher LI-catalysed ROS generation in the
organelle following UVA irradiation. We further demonstrate
that pre-treatment of human fibroblasts prior to UVA irradia-
tion with a mitochondria-targeted iron chelator suppresses the
LI-catalysed ROS production and cell death and halves both the
damage to mitochondrial membrane and ATP depletion in
the human derived FRDA fibroblasts. Similar results were also
observed in fibroblast cells derived from a mouse model of
FRDA. Our study describes a novel effect of mitochondrial
dysregulation and suggests a link between the high levels
of both mitochondrial redox active LI and ROS in FRDA skin
fibroblasts and their particular sensitivity to UVA. To our
knowledge this study is the first demonstration of this link.
These findings further suggest that topical use of mitochondria-
targeted iron chelators may be effective for skin photoprotection
of FRDA and possibly other disorders of mitochondria iron
overload exhibiting skin photosensitivity to sunlight.
Materials and methods
Iron chelator–peptide synthesis
The design, synthesis and characterization of compound 2
(‘‘cpd 2’’) and compound 13 (‘‘cpd 13’’), the chelator–peptides
used in this study have been documented elsewhere.10,29 Both
of these compounds have been previously shown to accumulate
selectively to the mitochondrial compartment, using quantita-
tive fluorescence microscopy.10,29
Reagents
All reagents used for cell cultivation were obtained from Life
Technologies (Paisley, Scotland). Phosphate buffered saline
(PBS) was from Oxoid Ltd (Basingstoke, UK). The mitochondrial
markers tetramethylrhodamine methyl ester (TMRM) and the
mitochondrial ROS indicator mitoSOXt red were purchased
from Invitrogen (Paisley, Scotland). Annexin V-FLUOS was from
Roche (Welwyn Garden City, UK). All other reagents were from
Sigma-Aldrich (Gillingham, UK).
Cell culture
The human primary skin fibroblasts GM04078 (male, 30 years
old), GM03816 (female, 36 years old) and GM03665 (female,
12 years old) from clinically affected Friedreich’s ataxia
patients and fibroblasts AG09429 (female, 25 years old) from
an apparently healthy (control) donor were obtained from the
Coriell Institute for Medical Research (Camden, New Jersey).
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These lines have been characterized elsewhere notably with
respect to their relative levels of FXN.40,41 Relative levels of FXN
protein: FRDA GM03816 (medium-low) 4 GM04078 (low) 4
GM03665 (very low). The human primary skin fibroblasts FEK4
which were used as a control line (courtesy of Prof. R. Tyrrell’s
laboratory, Switzerland) were isolated and expanded from
tissue samples obtained in full compliance with ethical regula-
tions and legislation in force at the time and respecting
complete donor confidentiality.10 FEK4 cells were isolated from
foreskin biopsies (passage 0), then subcultured and frozen
at increasing passages (up to p12). These stocks were available
for the present study. Two mouse fibroblast cell lines derived
from a transgenic mouse model of FRDA were also used: Y47R
(from control mouse) expresses normal level of FXN and YG8sR
(derived from ‘‘FRDA-like’’ mouse) expresses significantly reduced
level of FXN.42
The human primary fibroblast cells were routinely grown
in Earle’s MEM supplemented with 15% FCS, glutamine and
antibiotics, at 37 1C in a 5% CO2 atmosphere, as described
previously.10 The mouse cells were grown in DMEM supple-
mented with 10% FCS and antibiotics.42,43 For experiments
involving either chelator–peptide and/or mitoSOX delivery,
phenol red and antibiotics were omitted from the medium.
Compound delivery
The iron chelator–peptides (cpd 2 and cpd 13) were prepared as
100 mM stock solutions in DMSO (Z99.7% purity, cell culture
grade), diluted to the final desired concentration of 50 mM in
conditioned medium and added to cells overnight as described
previously.10,29 Final DMSO concentration in the medium dur-
ing treatment never exceeded 0.1%. On the day following
treatment, cells were irradiated where required and further
incubated in conditioned medium without compound for the
periods indicated.
Determination of mitochondrial labile iron
The principle and protocol of the determination of mitochondrial
LI are described in Supplementary Materials and methods and in
Fig. S2 (ESI†).
Determination of mitochondrial ROS production
Cells were grown in 6 cm plates in duplicates for three days to
reach 70–80% confluency. On day 2 of the seeding, cpd 2 was
added to the corresponding plates at a final concentration of
50 mM. Next day, cells were washed with PBS and either
irradiated with a UVA dose of 250 kJ m2 or sham-irradiated
(i.e. control). Immediately following treatment, cells were incu-
bated in serum-free and phenol red-free EMEM containing 1.5 mM
mitoSOXt red for 30 min at 37 1C. After two washes with PBS,
cells were collected by trypsinization and resuspended in PBS
containing 0.1% BSA. Cells were then counted and triplicates of
each condition, containing equal numbers of cells (0.1–0.2 
106 cells) were analysed using a spectrofluorimeter Clariostar
(BMG LABTECH Ltd, Aylesbury, UK) using PBS–0.1% BSA as
blank. Red fluorescence was detected using 451–522 nm
bandwidth for excitation and 550–650 nm bandwidth for emission,
for broad detection of mitochondrial ROS.44
UVA irradiation
Irradiations were performed in PBS at approximately 25 1C using a
broad spectrumSellas 4 kWUVA lamp (Sellas, Germany), as described
previously.45 The incident dose rate was ca. 0.2 kJ m2 s1. UV
doses were measured using an IL1700 radiometer (International
Light, Newbury, Massachusetts). Control cells were treated in the
same manner to irradiated ones, except that they were not
irradiated (i.e. sham-irradiated).
MTT assay
Cells grown in 35 mm dishes were treated as indicated in the
figure legends and grown for a further 24 h in conditioned
medium, after which the latter was removed and the cells were
incubated for 3 h at 37 1C in serum-free medium containing
0.5 mg mL1 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide). MTT solution was then removed and
DMSO was added to the cells in order to dissolve the formazan
formed. Absorbance was read at 550 nm using a spectrophoto-
meter Fluostar Optima (BMG LABTECH Ltd, Aylesbury, UK).
The percentage of viable cells was calculated by comparing the
absorbance of treated versus non-treated control cells.
Flow cytometry
All flow cytometry protocols are described in Supplementary
Materials and methods (ESI†).
ATP measurement
ATP production by cells following various treatments was
monitored with a luminometer (Turner Designs Model TD-20/20)
2 h after UVA, using the ViaLightt plus kit (Lonza Biologics plc,
Slough, UK) as described previously.46
Live cell microscopy
Bright-field images used to document morphological changes
following treatments were captured on aMotic invertedmicroscope
(model AE2000) (Motic Deutschland GmbH, Wetzlar, Germany) via
a Moticam 580 digital camera and a Plan 10 objective.
Statistical methods
Results are expressed as the mean  standard deviation (SD).
Significant differences (P o 0.05) were determined by either
paired or unpaired t-test after one-way analysis of variance.
Results
Fibroblasts isolated from Friedreich’s ataxia patients show
acute photosensitivity to biologically relevant doses of UVA
We first investigated the sensitivity of primary fibroblast cell
cultures derived fromhealthy patients and from patients diagnosed
with FRDA, to a range of physiologically and environmentally
relevant UVA doses. The MTT assay was used as a measurement
of viable cell metabolism. Primary skin fibroblasts from FRDA
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patients are deficient in FXN and have been shown to provide a
suitable model of the signature molecular characteristics of
the disease.19 The cell lines were challenged with increasing
doses of UVA ranging from 100 to 500 kJ m2 (ca. 30 min to
2.6 h exposure to sunlight at sea level47) and the MTT assay was
performed 24 h post-irradiation (Fig. 1a). At a dose as low as
100 kJ m2, the sensitivity of the FRDA lines GM03816 and
GM04078 was ca. 10% higher than that of control cell lines.
At a dose of 250 kJ m2 (i.e. equivalent to ca. 77 min exposure to
sunlight at sea level) all three FRDA cell lines displayed an
increasingly higher sensitivity than their healthy counterparts,
with GM04078 and GM03665 being ca. 3-fold more sensitive.
At the highest dose of 500 kJ m2 (equivalent to ca. 154 min
sunlight at sea level), the sensitivity of the FRDA lines rose up to
10-fold over that of cells from healthy donors. Our data show
that FRDA skin cells are more sensitive than their healthy
counterparts to physiologically relevant doses of UVA. Micro-
scopic images of control (AG09429) and FRDA (GM04078) cells
irradiated at 250 kJ m2 UVA capture the morphological changes
24 h post-treatment (Fig. 1c). Cell swelling, indicative of death by
necrosis is visible in the FRDA cells, whereas control cells appear
essentially unaffected.
We then investigated whether the differential sensitivity
to UVA observed in the human fibroblasts also held true in
cells derived from a mouse model of FRDA.42 In this model,
FRDA mouse (YG8sR) carries the FXN transgene from an FRDA
patient, and thus expresses low levels of FXN compared to
control mouse (Y47R) which expresses the FXN transgene from
an unaffected donor. YG8sR and Y47R fibroblasts were irra-
diated at UVA doses from 50 up to 250 kJ m2 and cell viability
was assessed by MTT 24 h post-irradiation (Fig. 1b). YG8sR cells
were more sensitive than control Y47R cells in the UVA dose
range from 150 up to 250 kJ m2, displaying up to 2-fold
difference in viability. Microscopic images of cells irradiated
at a UVA dose of 150 kJ m2 document the morphological
changes 24 h post-treatment (Fig. 1d).
A mitochondria-targeted iron chelator rescues fibroblasts
isolated from Friedreich’s ataxia patients from UVA-induced
cell death
In recent work, we reported the effectiveness of a mitochondria-
targeted iron chelator peptide, cpd 2 (Fig. 2a) in protecting
human skin fibroblasts in culture against UVA-induced mito-
chondrial damage, loss of ATP and cell death.10 The chimeric
compound which is based on amitochondria-tropic ‘‘SS peptide’’
carries three iron-chelating moieties, circled in dotted lines.
We sought to investigate as a first step whether cpd 2 would be
able to protect cells from FRDA patients from UVA-induced cell
death. For this purpose, cells were pre-treated (or not) with the
compound as indicated in Materials and methods, then irra-
diated with a UVA dose of 500 kJ m2 and live and dead/dying
cells were scored 24 h following irradiation using flow cytometry
and dual labelling of cells with fluorescently-labelled Annexin V
and propidium iodide (PI). This technique allows to determine
Fig. 1 FRDA fibroblasts are significantly more sensitive to UVA than their healthy counterparts. Cells were irradiated with increasing doses of UVA
radiation and cell metabolic activity was assessed by MTT 24 h post-treatment. Dose–response curves are shown for the human fibroblasts (a) and for the
mouse fibroblasts (b). Curves are representative of n = 3–8 independent experiments in (a) and n = 3–6 in (b). * significantly different (p o 0.05) from
control cell lines at corresponding dose. (c) Bright-field images were captured 24 h following irradiation of human fibroblasts with 250 kJ m2 UVA or
(d) mouse fibroblasts with 150 kJ m2 UVA. Cellular damage (arrows in inset) in the form of cell swelling and cell debris is visible after UVA irradiation.
Scale bar: 50 mm.
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whether cells are viable, apoptotic or necrotic via differences in
plasma membrane integrity and permeability. Percentages of live
cells obtained are plotted as bar charts in Fig. 3a for the FRDA
cell lines GM03816 and GM04078 using AG09429 as control.
Non-irradiated cells from all three cell lines display similar levels
of live cells (90–95%). Upon irradiation (500 kJ m2), the popula-
tion of live AG09429 cells decreased by ca. 10%. In stark contrast,
irradiated FRDA GM03816 and GM04078 cells incurred a signifi-
cant drop of 50–60% of viable cells compared to non-irradiated
sample. However, pre-treatment with cpd 2 prior to irradiation
Fig. 2 Structures of the mitochondrial iron chelator–peptides (‘‘compounds 2 and 13’’). The structures of the compounds used in this study are depicted
with their ionized functions at pH 7.4. (a) The three catechol functions (circled) form the iron-binding moieties which together bind iron as a hexadentate
chelator for compound 2. (b) Likewise, the hydroxypyridinone chelating moiety in compound 13 is circled and the fluorescent probe dansyl is coloured
in red.
Fig. 3 The chelator–peptide (compound 2) fully protects FRDA fibroblasts against UVA-induced cell death. Human fibroblasts (a) and mouse fibroblasts
(b) were treated (or not) overnight with 50 mM compound 2, then irradiated with UVA and the percentage of live cells was determined 24 h post-
treatment by flow cytometric Annexin V/PI double-labelling. UVA doses used: 500 kJ m2 for human cells, 250 kJ m2 for mouse cells. Results from 3–6
independent experiments are expressed as means  standard deviation (SD) of percentage live cells. * significantly different (p o 0.05) from irradiated
control cells. † significantly different (p o 0.05) from corresponding sample irradiated with UVA alone. Representative dot-plots shown for human
fibroblasts (c) and for mouse fibroblasts (d).
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effectively restored viability of control AG09429 cells, but also of
the two FRDA fibroblasts to the level of untreated sample. Visual
inspection of microscopy images of these experiments (Fig. S1a,
ESI†) highlights the morphological changes indicative of cell
death in FRDA cells following UVA irradiation alone, and the
robust protection afforded by cpd 2. Representative dot plots of
the results obtained for AG09429 and GM04078 are shown
(Fig. 3c), in which live cells occupy the lower left-hand side
quadrant (negative for both dyes) of each graph.
We then sought to interrogate the responsiveness of the
mouse cell lines Y47R and YG8sR to cpd 2 following UVA insult.
In view of the observed higher sensitivity of mouse fibroblasts
(ca. 2–2.5-fold) to UVA compared to human fibroblasts (see
Fig. 1), we chose the lower dose of 250 kJ m2 (approximately
equitoxic to 500 kJ m2 in human FRDA fibroblasts) to carry out
our investigation and cells were pre-treated (or not) with cpd 2
as in Fig. 3a prior to irradiation. As can be seen in Fig. 3b, the
irradiation treatment caused a drop of 10% live cells in Y47R
cells, whereas the FRDA YG8sR cells sustained a much greater
loss of ca. 40% live cells. Pre-treatment of cells with cpd 2 prior
to irradiation restored the percentage live cells to its value in
untreated sample in Y47R and to ca. 85% of its value in
untreated sample in YG8sR. Representative dot plots from
these experiments are depicted in Fig. 3d. Microscopy images
of these experiments (Fig. S1b, ESI†) document the marked
morphological changes undergone by the FRDA cells following
UVA irradiation and their disappearance in cells pre-treated
with cpd 2. Taken together, these data show that cpd 2 is
capable of effectively protecting highly UVA-sensitive FRDA
cells, from both patients and a mouse model of FRDA against
UVA-induced death.
Skin fibroblasts from patients with FRDA have higher basal
mitochondrial LI and UVA-induced ROS levels than their
healthy counterparts
In order to gain further understanding of the role of mitochondrial
LI in the higher phototoxicity of UVA to skin fibroblasts from
patients with FRDA, we sought to measure the level of mito-
chondrial LI in the cell lines used in this study. For this
purpose, we used a sensitive mitochondria-targeted iron-
selective ‘‘turn-off’’ fluorescent sensor – cpd 13 (Fig. 2b and
Fig. S2, ESI†), which we previously developed and characterized
in human primary fibroblasts.29 cpd 13, which carries a
hydroxypyridinone-based function can selectively sense varia-
tions in intracellular concentrations of mitochondrial LI. Our
results (Fig. 4) show that the mean levels of mitochondrial LI in
FRDA cells GM03816 and GM04078 (1.11 mM  0.37) are on
average 6.5-fold higher than those in cells from healthy donors
FEK4 and AG09429 (0.17 mM  0.12). In order to assess if the
higher level of mitochondrial LI in FRDA cells was correlated
with increased oxidative stress, we measured the levels of
mitochondrial ROS by spectrofluorimetry in cells exposed (or
not) to UVA-mediated oxidative stress. For this purpose, we
used the mitochondrial fluorescent probe mitoSOX, whose
fluorescence increases following oxidation by ROS.44 Cells, either
non-irradiated or irradiated with a UVA dose of 250 kJ m2 were
analysed immediately following treatment for changes in mito-
chondrial ROS, as described in Materials and methods (Fig. 5).
UVA irradiation treatment increased the levels of mitochondrial
ROS production over background by a factor of ca. 2.1 on average
in FRDA cell lines and by 1.2-fold on average in healthy cell lines.
This represents an average increase of 1.8-fold of mitochondrial
ROS production in the FRDA cells studied compared to healthy
counterparts. Preincubation of cells with cpd 2 prior to UVA
irradiation efficiently prevented the UVA-induced mitochondrial
ROS production increase in cells from both healthy and FRDA
donors.
Mitochondria of fibroblasts from patients with Friedreich’s
ataxia are markedly more sensitive to UVA compared
to those from their healthy counterparts
The pathological accumulation of iron in the mitochondria of
patients with FRDA is thought to be a strong contributor to the
observed enhanced sensitivity to oxidative stress of the cells of
those patients. We hypothesized that this mechanism could
exacerbate the sensitivity of mitochondria from FRDA patients
to damage induced by environmental solar UVA and that this
could potentially be counteracted by the use of a mitochondria-
specific iron chelator. Mitochondria functionality can be
assessed by the integrity of mitochondria membrane potential
(Dcm) using flow cytometry and the fluorescent cationic dye
tetramethylrhodamine methyl ester (TMRM) which accumu-
lates only in intact mitochondria. Mitochondrial membrane
depolarization translates into a decrease in TMRM fluores-
cence. Human healthy and FRDA fibroblasts were irradiated
with a UVA dose of 250 kJ m2 and fluorescence was monitored
2 h post-irradiation, a time-point at which we have previously
shown in healthy fibroblasts that both the level of labile iron in
the cell and damage to membranes are at their highest.6–8 The
UVA dose of 250 kJ m2 was chosen so that the resulting
membrane damage would not lead to significant dye leakage,
which would invalidate the assay. The results, reported as a bar
Fig. 4 Mitochondria from FRDA fibroblasts have significantly higher levels
of labile iron compared to healthy fibroblasts. Cells were treated (or not)
with the hexadentate chelator DFO followed by 50 mM of compound 13 as
described in materials and methods. Cells were then harvested and their
fluorescence was measured. Data were compiled from n = 3–5 measure-
ments per cell line. Mitochondrial LI levels are represented as fold change
relating to control FEK4 cells (taken as 1). * significantly different (po 0.05)
from healthy cells.
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chart in Fig. 6a, are expressed as percentage fluorescence of
non-irradiated cells (i.e. control). In healthy AG09429 cells,
irradiation caused a non-significant drop in TMRM fluores-
cence of ca. 10% compared to control cells. In contrast, in both
FRDA cell lines GM03816 and GM04078, a significant decrease
of respectively 70 and 80% in TMRM fluorescence could be
observed, indicative of the exacerbated sensitivity of mitochon-
dria. Pre-treatment of FRDA cells with cpd 2 prior to irradiation
afforded a significant 2-fold and 3-fold protection to GM03816
and GM04078 cells, respectively while healthy AG09429 cells
fully recovered their mitochondria integrity. We then interro-
gated the mouse fibroblasts similarly to the human fibroblasts
above but using the UVA dose of 150 kJ m2 (approximately
equitoxic to 250 kJ m2 in human FRDA fibroblasts). The FRDA
YG8sR cells showed much higher sensitivity to UVA irradiation
when compared to their healthy counterparts Y47R, with a ca. 50%
drop in TMRM fluorescence compared to 10% in Y47R (Fig. 6b).
When pre-treated with compound 2 prior to irradiation, YG8sR
cells displayed a 2-fold recovery of fluorescence signal, indicating
significant mitochondria membrane protection, while Y47R cells
fully recovered their mitochondrial membrane potential.
We have previously shown that the measurement of cellular
ATP is a good indicator of mitochondria integrity following
exposure to biologically relevant doses of UVA radiation.6 We
therefore sought to assess whether the observed high sensitivity
of mitochondria of FRDA cells to UVA correlated with the levels of
cellular ATP. Cells were treated under the same conditions as those
employed to assess mitochondria integrity using TMRM, and ATP
levels were measured 2 h post-irradiation (Fig. 7a). UVA irradiation
of AG09429 cells caused a reduction in ATP levels of ca. 25%
compared to non-irradiated controls, while ATP levels in irradiated
FRDA cells were reduced by up to 70%. Pre-treatment of cells with
cpd 2 prior to irradiation afforded a ca. 30% recovery of ATP levels
in both FRDA GM03816 and GM04078 cells, while a full rescue of
ATP levels in AG09429 was recorded. We then interrogated Y47R
and YG8sR mouse cells as in the corresponding TMRM experi-
ments (Fig. 7b). While ATP levels in Y47R cells were reduced by
10% following UVA irradiation, they were decreased by 30% in
FRDA YG8sR cells. Significantly, pre-treatment of both Y47R and
YG8sR cells with cpd 2 prior to irradiation almost fully restored
ATP levels. In summary, these data demonstrate that mitochondria
of fibroblasts from both FRDA patients and a mouse model of
the disease are more sensitive to UVA-induced damage than their
healthy counterparts, as measured by loss of mitochondrial
membrane potential (cm) and decreased ATP production. Further-
more, we show that both mitochondria integrity and functionality
can be protected by pre-treatment of cells with a mitochondria-
targeted iron chelator.
Discussion
Our findings reveal an important link between FRDA as a
disease of mitochondrial iron overload and skin fibroblast
Fig. 5 Mitochondria from FRDA fibroblasts have higher levels of ROS
compared to healthy fibroblasts. Cells were treated (or not) with cpd 2,
then with a UVA dose of 250 kJ m2 and analysed using the mitochondrial
probe mitoSOX red as described in materials and methods. Data were
compiled from n = 3–4 measurements per cell line. Mitochondrial ROS
levels are indicated as fold change relating to their corresponding uni-
rradiated control cells (taken as 1). * significantly different (po 0.05) from
corresponding unirradiated control cells. † significantly different (po 0.05)
from corresponding sample irradiated with UVA alone.
Fig. 6 UVA-induced damage to the mitochondria of FRDA cells is efficiently reduced by the mitochondrial iron chelator. Human fibroblasts (a) and
mouse fibroblasts (b) were treated (or not) overnight with 50 mM compound 2, then irradiated with UVA and the magnitude of mitochondria membrane
depolarisation was measured 2 h post-treatment by flow cytometry using TMRM labelling. UVA doses: 250 kJ m2 for human cells, 150 kJ m2 for mouse
cells. Results from 3–6 independent experiments are expressed as means  SD of percentage fluorescence compared to untreated control cells.
* significantly different (po 0.05) from irradiated control cells. † significantly different (po 0.05) from corresponding sample irradiated with UVA alone.
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sensitivity to UVA. Taken together, these results provide a link
between the higher levels of mitochondrial LIP in FRDA cells
and the higher oxidative stress observed in these organelles.
These results are also in line with the observed much higher
sensitivity of FRDA fibroblasts to UVA-induced damage com-
pared to healthy counterparts. A high concentration of resident
redox-active mitochondrial iron provides a rational explanation
to the high oxidative burden in FRDA mitochondria described
by others as a result of defective expression of frataxin.12 Such
burden would be exacerbated upon exposure of cells to UVA
radiation. The complete protection afforded by cpd 2 against
UVA-induced cell death supports the crucial role of mitochondrial
LI in this process. We suggest that the level of mitochondrial LI
could be used a prognostic indicator for skin photosensitivity, with
particular relevance for FRDA patients but also, for patients with
other disease of mitochondrial iron overload.
Furthermore, we show that both mitochondria integrity and
functionality can be protected, at least in part by pre-treatment
of cells with a mitochondria-targeted iron chelator. Exposure
of cells to cumulative biologically relevant doses of UVA has
been shown to induce damage to mitochondrial DNA48 with
concurrent effect on cell viability. Oxidation of sensitive mito-
chondrial proteins such as those containing ISCs can also occur
as a result of excessive oxidative stress catalysed by excess
mitochondrial LI, thereby impairing mitochondrial functions.
Taken together our results are in favour of the concept that
mitochondrial iron overload in FRDA skin cells will exacerbate
UVA-induced ROS-mediated damage to mitochondrial compo-
nents, especially ISC-containing proteins, resulting in compro-
mised energy production, loss of mitochondrial function and
cell death. The altered antioxidant response in FRDA cells18,19
will almost certainly be an important contributing factor in
their greater sensitivity to UVA, the oxidizing component of
sunlight. However, our data suggest that mitochondrial iron is
the determining factor.
The high sensitivity of FRDA fibroblasts to the oxidative
solar UVA waveband has practical implications. Despite lying
deep in the skin, fibroblasts are a major target for skin photo-
damage by long-wave UVA since up to 50% of this UV range
penetrates into the dermis.49 UVA directly affects the architec-
ture of the dermis via the increase in matrix metalloproteinases
activity, resulting in remodelling of the extracellular matrix
through degradation of collagens and elastin which are
hallmarks of photoaged skin.50,51 Our findings highlight the
possibility that other skin cell sensitization may occur in other
diseases characterised by mitochondria iron overload. In view
of this, topical application of mitochondria-targeted iron
chelators such as cpd 2 as part of a sunscreen formulation
could be envisioned as a valuable approach for skin photo-
protection of FRDA patients.
Finally, the results obtained in the mouse fibroblast model
of FRDA recapitulate the trend in differential sensitivities
observed in human fibroblasts between healthy and FRDA cells,
albeit to a lesser degree of intensity, thereby broadening the
validity of this study model for the field of FRDA research.
Conclusion
We have shown that skin fibroblasts from FRDA patients are
highly sensitive to exposure to UVA. Our results altogether tie in
with the concept that mitochondrial redox active iron overload
is a crucial component of this sensitivity due to its ability to
participate in Fenton chemistry, generating highly damaging
ROS in UVA-irradiated FRDA fibroblasts.52 The knowledge
inferred from our study has relevance for healthcare profes-
sionals in prevention of sun-induced skin damage (including
photoaging) and could function as a valuable early cautionary
indicator to forewarn patients with FRDA (estimated prevalence
of about 1 in 29 000 in Caucasians with a concentration of 1 in
20 000 in south-west Europe53,54). This may potentially extend
to other diseases of mitochondrial iron overload. Skin fibro-
blasts which can readily be obtained from FRDA patients could
be used as a predictive tool to determine their sensitivity to
UVA. Furthermore, they represent a useful model to test photo-
protective compounds including iron chelators, antioxidant
molecules and sunscreen ingredients. Finally, we present the
first application of our bespoke mitochondrial iron-selective
Fig. 7 The mitochondrial iron chelator mitigates the UVA-induced loss of ATP in FRDA fibroblasts. Human fibroblasts (a) and mouse fibroblasts (b) were
treated as in Fig. 6 and cellular ATP production was measured 2 h post-treatment. Results from 3–5 independent experiments are expressed as means 
SD of percentage ATP production compared to untreated control cells. * significantly different (p o 0.05) from irradiated control cells. † significantly
different (p o 0.05) from corresponding sample irradiated with UVA alone.
Paper Metallomics
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
9 
Fe
br
ua
ry
 2
01
9.
 D
ow
nl
oa
de
d 
on
 3
/4
/2
02
0 
4:
19
:1
0 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
664 | Metallomics, 2019, 11, 656--665 This journal is©The Royal Society of Chemistry 2019
sensor to measure mitochondrial redox-active iron levels in
healthy and FRDA skin fibroblasts. With this unique new tool,
this study is contributing to the development and validation of
novel techniques aimed at the measurement of iron in specific
organelles, with particular relevance to pathological conditions.
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